Back in 2013, when Dan Cadigan was first diagnosed with stage III lung cancer, his treatment options were limited to surgery followed by chemotherapy. However, at his one-year follow-up scan, they found nodules in both lungs and he was diagnosed with stage IV recurrent cancer.
Normally, it would have meant a return to chemo for treatment.
The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago June 3-7, 2022. Dr. Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, sat down with Dr. Charles Rudin to discuss key highlights from ASCO 2022 and what they mean for the lung cancer community.
Palliative care, or supportive care, often misunderstood as only end-of-life care, improves patients' quality of life while undergoing treatment. The goal of palliative care is to alleviate the symptoms and side effects caused by lung cancer or its treatment. It also can help you and your family deal with both the emotional aspects of your illness and any practical issues.
On April 21, LUNGevity’s Director of Community Outreach, Dr. Eugene Manley, Jr., moderated the first in a series of Conversations That Count, titled The Black Experience of Lung Cancer. As part of LUNGevity Foundation’s health equity webinar series, the following panelists came together via Facebook Live to share personal and professional stories of incredible tenacity in accessing lung cancer care:
LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows:
In 2021, LUNGevity Foundation announced our inaugural Health Equity and Inclusiveness Workforce Development Awards to help combat the lack of diversity among lung cancer researchers as well as disparities in the lung cancer research itself. To learn more about the health disparities research and why it matters to all people, LUNGevity Foundation spoke with Robert Winn, MD, director of the Virginia Commonwealth University Massey Cancer Center and member of LUNGevity’s Board of Directors.
